Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy for ALS delivers.

Séverine Boillée1, Don W Cleveland

  • 1Ludwig Institute for Cancer Research and Departments of Cellular and Molecular Medicine and Neurosciences, University of California, 9500 Gilman Drive, La Jolla, CA 92093-0670, USA.

Trends in Neurosciences
|April 28, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An emergent disease-associated motor neuron state precedes cell death in ALS.

Cell·2026
Same author

Mutant SOD1 expressed by oligodendrocytes aggregates in myelinic nanochannels and accelerates disease progression in familial ALS mice.

bioRxiv : the preprint server for biology·2026
Same author

Statins and genetic inhibition of the mevalonate pathway activate an ATF3-STMN2 regenerative program.

bioRxiv : the preprint server for biology·2026
Same author

Neuropathological analysis of an ALS patient carrying a SOD1 missense variant and a C9orf72 repeat expansion.

Acta neuropathologica·2026
Same author

Dual-targeting snRNA gene therapy rescues STMN2 and UNC13A splicing in TDP-43 proteinopathies.

bioRxiv : the preprint server for biology·2026
Same author

Chromothripsis and ecDNA initiated by N4BP2 nuclease fragmentation of cytoplasm-exposed chromosomes.

Science (New York, N.Y.)·2025

Researchers slowed amyotrophic lateral sclerosis (ALS) progression in mice by using adeno-associated virus (AAV) to deliver insulin-like growth factor 1 (IGF-1) directly to motor neurons. This gene therapy approach offers new hope for treating this devastating neurodegenerative disease.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by motor neuron loss.
  • Previous attempts using neurotrophins like insulin-like growth factor 1 (IGF-1) in human trials have yielded disappointing results.
  • Developing effective therapeutic strategies for ALS remains a significant challenge.

Purpose of the Study:

  • To investigate the potential of gene therapy for ALS treatment.
  • To determine if targeted delivery of IGF-1 to motor neurons can slow disease progression.
  • To evaluate the efficacy of recombinant adeno-associated virus (AAV) for gene delivery in an ALS mouse model.

Main Methods:

  • Utilized a transgenic mouse model of ALS.

Related Experiment Videos

  • Administered recombinant adeno-associated virus (AAV) vector carrying the IGF-1 gene via retrograde delivery into muscle tissue.
  • Forced motor neurons to produce IGF-1.

    • Main Results:

    • Successfully slowed disease progression in ALS transgenic mice.
    • Demonstrated effective gene expression and protein production of IGF-1 in motor neurons.
    • Observed a therapeutic benefit in the animal model.

    Conclusions:

    • Retrograde delivery of AAV to induce motor neuron production of IGF-1 is a viable strategy for slowing ALS progression.
    • The established clinical safety of IGF-1 and AAV vectors supports the potential for human application.
    • This approach offers a promising new avenue for the development of effective ALS therapies.